SCHEMBL16624206

SCHEMBL16624206

COCc1cc(-c2ccc(F)cc2)c(C2CC2)cc1C=O

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SSTR5 P35346 5/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
FFAR4 Q5NUL3 1/20 0.33
ERN1 O75460 2/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
PTGDR2 Q9Y5Y4 2/20 0.33
PTGDR Q13258 1/20 0.33
KDM4E B2RXH2 1/20 0.32
HTT P42858 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
FFAR2 O15552 1/20 0.32
SCN9A Q15858 1/20 0.32
GCGR P47871 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16055932 0.87 SSTR5 (0.42) SSTR5ALDH1A1MAPTL3MBTL1PTGDR2
SCHEMBL16054923 0.81 ERN1 (0.42) SSTR5ALDH1A1MAPTERN1L3MBTL1
SCHEMBL16624205 0.81 GCGR (0.39) SSTR5MAPTFFAR4L3MBTL1PTGDR2
SCHEMBL16056271 0.81 ALDH1A1 (0.42) SSTR5ALDH1A1MAPTFFAR4ERN1
SCHEMBL16055600 0.80 PTGS2 (0.37) ALDH1A1MAPTPTGDR2PTGDRKDM4E
SCHEMBL17535564 0.80 ALDH1A1 (0.44) SSTR5ALDH1A1MAPTFFAR4ERN1
SCHEMBL16055039 0.79 ERN1 (0.42) SSTR5ALDH1A1MAPTERN1L3MBTL1
SCHEMBL16055474 0.78 SSTR5 (0.42) SSTR5ALDH1A1MAPTFFAR4PTGDR2
SCHEMBL16055517 0.77 ESR2 (0.37) ALDH1A1MAPTERN1PTGDR2PTGDR
SCHEMBL17535422 0.76 ALDH1A1 (0.42) SSTR5ALDH1A1MAPTFFAR4ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-9353108-B2 Tetrahydronaphthyridine somatostatin receptor 5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-05-31 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed
US-20150099777-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099777-A1 HETEROCYCLIC COMPOUND SSTR5, SSTR4, SSTR2 SSTR5 1/4885ALDH1A1 3197/4885MAPT 3648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.